Background & Aims: Sofosbuvir is a powerful drug for the treatment of
hepatitis C virus (HCV) infection. In comparison to preceding remedies, sofosbuvirbased
regimens provide a higher cure rate, fewer side effects, and much lower duration
of treatment. The aim of the work was to assess the efficacy and safety of sofosbuvir
plus ribavirin with or without peginterferon-alfa in the treatment of a cohort of
Egyptian patients with hepatitis C virus infection.
Methods: Two hundred treatment naive patients who were HCV-antibody positive
and HCV RNA by PCR positive aged more than 18 years were enrolled in the study
and patients were classified into two groups: Group I which included 100 patients
who received dual therapy with sofosbuvir plus oral weight based ribavirin for 24
weeks and Group II which included 100 patients on triple therapy with sofosbuvir
plus oral weight based ribavirin (as with the dual therapy) and a 180 mcg Peg-INF
alpha 2a subcutaneous injection weekly for 12 weeks. The primary end point was a
sustained virological response at 12 weeks after end of the treatment determined by
quantitative PCR for HCV.
Results: Both patients groups had high sustained virological response that was higher
in patients receiving triple than dual therapy (94% vs 83%). The adverse events
that occurred in the two groups of patients were more evident in a group of patients
receiving triple therapy. The side effects were mainly flu like symptoms.
Conclusions: The triple regimen of Pegylated interferon, sofosbuvir plus ribavirin is
safe and effective in the treatment of Egyptian patients with hepatitis C virus as well
as sofosbuvir and ribavirin alone wit